To ensure a successful drug launch, biotech companies must start their commercialization planning at least 18 months in advance. This lead time is essential for deeply understanding the patient journey, identifying treatment barriers, and aligning clinical trials with outcomes that truly matter to patients and payers.

Zyda raised funds primarily from urologists and urogynecologists. These clinician-investors already understood the market need, provided crucial industry connections (like finding a clinical trial investigator), and became influential early prescribers, dramatically accelerating market entry and validation.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Before its US FDA filing, Sedana Medical established a strong commercial footprint in Europe, particularly Germany, where it serves over half of hospitals with ICUs. This real-world experience with hundreds of thousands of patients provides a robust proof-of-concept that de-risks the US launch for investors and potential customers.

CervoMed hired its Chief Commercial Officer before starting Phase III to ensure the trial design supports future commercialization. This avoids the common mistake of treating market access as an afterthought to be "bolted on" after receiving positive data.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

To prepare for launch, Celcuity initiated its commercialization process years in advance, assuming clinical success. The process was phased: it started with senior leadership, then built out functions like market access, and only hired the full sales force in the final quarters before launch.

Successfully launching in the U.S. market starts long before regulatory approval. Startups must pre-emptively map the entire adoption ecosystem—from patients to providers to clinicians—and develop tailored messaging for each stakeholder's unique priorities.

Don't wait until after FDA approval to think about reimbursement. Smart biotechs engage with payers early and build payer-valued outcomes directly into Phase 2/3 trials. This creates a ready-made value dossier for payers alongside the regulatory submission package.